All In Biotech

Drug Trial Radar · NCT05332340

Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered

Phase 1 Clinical Trial Study to Evaluate Pharmacokinetics and Safety Profile of BZ371A in a Gel Formulation, Applied on Healthy Men and Women Genitals

Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Nov 16, 2022

Primary completion

Nov 30, 2022

Study completion Nov 30, 2022

Sponsor

Lead sponsor
Biozeus Biopharmaceutical S.A.Industry
Sponsor type
Industry
Collaborators
Azidus Brasil Scientific Research and Development Ltda
First posted
Apr 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate pharmacokinetics, safety and tolerability profile of BZ371A topically administered in healthy patients.

Conditions

  • Erectile Dysfunction Following Radical Prostatectomy
  • Erectile Dysfunction
  • Prostate Cancer
  • Radical Prostatectomy

Interventions

  • BZ371ADrug

    Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: 0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
  2. T1/2Time frame: 0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
  3. AUCTime frame: 0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
  4. Clearance (CL)Time frame: 0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
  5. VdTime frame: 0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
  6. Adverse Effects EvaluationTime frame: All adverse effect will be collected from the beginning of the study up to one week after drug administration
  7. Physical ExamTime frame: Baseline and 1 week
  8. Change in SBPTime frame: Baseline and 1 week
  9. Change in DBPTime frame: Baseline and 1 week
  10. Change in Heart RateTime frame: Baseline and 1 week
  11. Change in Respiratory RateTime frame: Baseline and 1 week
  12. Change in TemperatureTime frame: Baseline and 1 week
  13. Basal Chest Electrocardiogram (ECG)Time frame: Baseline and 1 week
  14. Blood EvaluationTime frame: Baseline and 1 day
  15. Urine EvaluationTime frame: Baseline and 1 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Azidus Brasil Pesquisa Científica e Desenvolvimento

    Valinhos, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.